Galectin Therapeutics Inc. 10-Q Summary
Business Context and Reporting Period
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. Its lead candidate is belapectin, focused primarily on NASH cirrhosis and prevention of esophageal varices. The filing covers the three and six months ended June 30, 2023 and is unaudited.
The company has no commercial revenue and has incurred losses since inception. The NAVIGATE Phase 2b/3 trial completed randomization of 357 patients in February 2023; management expects topline interim-analysis results in fall 2024.
Key Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.4 million | $16.2 million |
| General and administrative expense | $1.6 million | $3.2 million |
| Total operating expense | $9.0 million | $19.3 million |
| Net loss | $9.1 million | $20.6 million |
| Net loss applicable to common stockholders | $9.2 million | $20.7 million |
| Net loss per share | $0.15 | $0.35 |
| Net cash used in operating activities | Not separately provided | $20.6 million |
At June 30, 2023, cash and cash equivalents were $18.0 million, compared with $18.6 million at December 31, 2022. Total assets were $20.1 million, total liabilities were $71.2 million, and stockholders’ deficit was $52.9 million.
Debt included approximately $30.4 million of related-party convertible notes, plus $29.9 million borrowed under a related-party convertible line of credit. The line of credit has a total commitment of $60.0 million, with $30.0 million remaining available at June 30, 2023. The company also reported $0.9 million of derivative liabilities and $1.7 million of redeemable convertible preferred stock.
Operating cash use was funded partly by $20.0 million of net proceeds from draws under the related-party line of credit. There were no material market-risk exposures identified beyond interest-rate risk on cash and cash equivalents.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased to $20.6 million from $19.5 million, while net loss applicable to common stockholders increased to $20.7 million from $19.6 million.
- Six-month operating cash use increased to $20.6 million from $15.5 million, primarily reflecting NAVIGATE-related activities and higher cash operating expenses.
- Research and development expense was essentially flat for the six-month period, increasing $38,000, but declined 9% in the second quarter due mainly to the timing of NAVIGATE activities.
- Clinical-program spending declined to $12.3 million from $13.7 million for the six months, while preclinical spending increased to $1.5 million from $0.7 million.
- General and administrative expense declined 8% for the six months, primarily due to lower non-cash stock-based compensation.
- Interest expense increased to $1.1 million from $0.5 million for the six months, mainly because of borrowings under the convertible line of credit and related debt discounts.
- The company drew an additional $10.0 million under the line of credit on March 31, 2023 and another $10.0 million on June 30, 2023. Each draw was accompanied by warrants for 200,000 common shares.
- Common shares outstanding increased to 59.6 million from 59.4 million at December 31, 2022. Potential dilution included approximately 12.0 million warrants, 6.3 million options, 6.1 million shares issuable upon conversion of the notes, and 10.2 million shares issuable upon conversion of the line of credit.
Guidance, Outlook, Risks and Unusual Items
Management believes available cash and the remaining line-of-credit capacity are sufficient to fund currently planned operations through at least December 31, 2024. The company expects to require additional financing thereafter and intends to pursue debt or equity financing, collaborations, partnerships, or other strategic transactions. No assurance is provided that financing will be available on acceptable terms.
The proposed Phase 2 trial of belapectin in combination with a checkpoint inhibitor for recurrent or metastatic head and neck cancer remains dependent on financing. The company continues to evaluate strategic and financing options for that program.
- The company remains loss-making, has no revenue, and expects losses to continue for the foreseeable future.
- Clinical development, regulatory approval, patient recruitment, trial execution, safety and efficacy outcomes, and manufacturing remain significant uncertainties.
- NAVIGATE enrollment was affected by COVID-19 and weaker-than-expected European enrollment, although sites were activated in Latin America and final randomization was completed.
- Debt is concentrated with the chairman, Richard E. Uihlein. The notes and line-of-credit borrowings are convertible into common stock and may create substantial future dilution.
- Convertible notes totaling $30.0 million have stated maturities in 2025, unless converted, and line-of-credit principal and interest are due by January 31, 2026.
- Derivative liabilities are valued using Level 3 models and are sensitive to the company’s stock price, volatility, interest rates, and other assumptions.
- The filing reports no significant pending legal proceedings, no unregistered securities sales, and no material change in internal control over financial reporting.
Facts Investors Should Verify
- Progress toward the expected fall 2024 NAVIGATE interim-analysis topline results, including enrollment follow-up and data-readout timing.
- Cash burn, remaining line-of-credit availability, and the timing and terms of any required financing after December 2024.
- Outstanding principal, accrued interest, conversion terms, and maturity dates for all related-party debt.
- Potential dilution from approximately 12.0 million warrants, 6.3 million options, convertible debt, preferred stock, and future line-of-credit draws.
- Financing and regulatory status of the proposed belapectin oncology trial.
- Clinical-trial accrual estimates and whether actual vendor activity could require future research-and-development expense adjustments.